The DOI matches its Crossref record.
Controlled Trial of 2, 4, and 6 Months of Pyrazinamide in 6-Month, Three-Times-Weekly Regimens for Smear-positive Pulmonary Tuberculosis, Including an Assessment of a Combined Preparation of Isoniazid, Rifampin, and Pyrazinamide: Results at 30 Months
Abstract
In a study in Hong Kong 1, 386 Chinese patiente with sputum smear-positive pulmonary tuberculosis were allocated at random to four 6-month regimens of chemotherapy, all given three times weekly from the start and all containing isoniazid (H) and rifampin (R) throughout. Three contained streptomycin (S) for the first 4 months and pyrazinamide (Z) for 2 months (Z2), 4 months (Z4), or 6 months (Z6); the fourth contained pyrazinamide for 6 months but no streptomycin (Z6noS). Every dose of all four regimens was given under the direct supervision of clinic staff on a predominantly outpatient basis. During the later part of the intake patienta were allocated at random to be given their HRZ either as a combined formulation (Rifater), each tablet containing 125 mg isoniazid, 100 mg rifampin, and 375 mg pyrazinamide, or as the three drugs separately. Among 892 assessable patiente with drug-susceptible strains of tubercle bacilli pretreatment, bacteriologic failure during chemotherapy occurred in 4, all Z6noS (2% of 224; p < 0.005 for the comparison with the S-containing regimens). During 30 months of follow-up after the end of chemotherapy, bacteriologic relapse occurred in 2 (3%) of 71 Z2, 2 (3%) of 72 Z4, 4 (6%) of 66 Z6, and 6 (9%) of 64 Z6noS patiente allocated to Rifater, and in 4 (3%) of 149 Z2, 8 (6%) of 133 Z4, 2 (1%) of 142 Z6, and 6 (4%) of 135 Z6noS patiente allocated to separate drugs. In the relapse rates there were no significant differences between the Rifater and separate drug regimens, the different durations of pyrazinamide, or the regimens with and without streptomycin. In view of the failures during chemotherapy in the Z6noS series, the Hong Kong Chest Service continues to give a fourth drug, usually streptomycin, during the first 2 months of Intermittent 6-month chemotherapy in the treatment of smear-positive patiente. Further studies on the value of a fourth drug, not only in intermittent but also in daily chemotherapy, are desirable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
The Effect of Directly Observed Therapy on the Rates of Drug Resistance and Relapse in Tuberculosis
Weis, S. E., Slocum, P. C., Blais, F. X., King, B., Nunn, M., Matney, G. B., Gomez, E., & Foresman, B. H. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404283301702 · Cited by 589
Tuberculous meningitis: many questions, too few answers
Thwaites, G. E., & Hien, T. T. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)01013-6 · Cited by 369
International Standards for Tuberculosis Care
Hopewell, P. C., Pai, M., Maher, D., Uplekar, M., & Raviglione, M. C. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70628-4 · Cited by 336
Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 Days
Jindani, A., Doré, C. J., & Mitchison, D. A. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200210-1125oc · Cited by 321
Metadata
- Authors
- Hong Kong Chest Service/British Medical Research Council
- Venue
- American Review of Respiratory Disease
- Publisher
- Oxford University Press (OUP)
- Published
- 1991-04
- Volume
- 143
- Issue
- 4_pt_1
- Pages
- 700-706
- ISSN
- 0003-0805 (ISSN-L)
- OpenAlex
- W4253099240
- Cited by
- 163
- References
- 0
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Controlled Trial of 2, 4, and 6 Months of Pyrazinamide in 6-Month, Three-Times-Weekly Regimens for Smear-positive Pulmonary Tuberculosis, Including an Assessment of a Combined Preparation of Isoniazid, Rifampin, and Pyrazinamide: Results at 30 Months. https://app.cochat.ai/papers/10.1164/ajrccm/143.4_pt_1.700
- The paper
- Hong Kong Chest Service/British Medical Research Council. (1991). Controlled Trial of 2, 4, and 6 Months of Pyrazinamide in 6-Month, Three-Times-Weekly Regimens for Smear-positive Pulmonary Tuberculosis, Including an Assessment of a Combined Preparation of Isoniazid, Rifampin, and Pyrazinamide: Results at 30 Months. American Review of Respiratory Disease. https://doi.org/10.1164/ajrccm/143.4_pt_1.700
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.